MX2010008196A - Derivados de acido 4-dimetilaminobutirico. - Google Patents

Derivados de acido 4-dimetilaminobutirico.

Info

Publication number
MX2010008196A
MX2010008196A MX2010008196A MX2010008196A MX2010008196A MX 2010008196 A MX2010008196 A MX 2010008196A MX 2010008196 A MX2010008196 A MX 2010008196A MX 2010008196 A MX2010008196 A MX 2010008196A MX 2010008196 A MX2010008196 A MX 2010008196A
Authority
MX
Mexico
Prior art keywords
acid derivatives
dimethylaminobutyric acid
activity
dimethylaminobutyric
cpt
Prior art date
Application number
MX2010008196A
Other languages
English (en)
Inventor
Gerald Lewis Kaplan
Jefferson Wright Tilley
Patrizio Mattei
Odile Chomienne
Mirjana Andjelkovic
Simona M Ceccarelli
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40897585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010008196A publication Critical patent/MX2010008196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos derivados ácido 4-dimetilaminobutírico de la fórmula (ver fórmula (I)) en donde A1, A2, R1, m y n tienen los significados definidos en la descripción y en las reivindicaciones, así como a sus sales farmacéuticamente aceptables. Estos compuestos inhiben la actividad de la carnitina-palmitoil-transferasa (CPT), en particular al actividad de la CPT2, y pueden utilizarse como medicamentos.
MX2010008196A 2008-04-29 2009-04-20 Derivados de acido 4-dimetilaminobutirico. MX2010008196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155323 2008-04-29
PCT/EP2009/054635 WO2009132978A1 (en) 2008-04-29 2009-04-20 4-dimethylaminobutyric acid derivatives

Publications (1)

Publication Number Publication Date
MX2010008196A true MX2010008196A (es) 2010-08-11

Family

ID=40897585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008196A MX2010008196A (es) 2008-04-29 2009-04-20 Derivados de acido 4-dimetilaminobutirico.

Country Status (18)

Country Link
US (2) US8344027B2 (es)
EP (1) EP2268606B1 (es)
JP (1) JP5474047B2 (es)
KR (1) KR101225223B1 (es)
CN (1) CN101952243B (es)
AR (1) AR073842A1 (es)
AU (1) AU2009242240B2 (es)
BR (1) BRPI0911159A2 (es)
CA (1) CA2722087C (es)
CL (1) CL2009001006A1 (es)
ES (1) ES2507089T3 (es)
IL (1) IL206524A0 (es)
MX (1) MX2010008196A (es)
PE (1) PE20091735A1 (es)
RU (1) RU2474573C2 (es)
TW (1) TWI369344B (es)
WO (1) WO2009132978A1 (es)
ZA (1) ZA201005321B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525340T3 (es) * 2008-04-29 2014-12-22 F. Hoffmann-La Roche Ag 4-butiratos de trimetilamonio como inhibidores de la CPT2
AU2009242240B2 (en) 2008-04-29 2011-09-22 F. Hoffmann-La Roche Ag 4-dimethylaminobutyric acid derivatives
FR2951448B1 (fr) * 2009-10-15 2012-09-07 Centre Nat Rech Scient Synthese de polyurethane par autocondensation
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105859658A (zh) * 2016-05-12 2016-08-17 青岛大学 (r)-2-羟基-n-((2s,3s)-2-((r,e)-1-羟基十五烷-4-烯-1-基) 氧杂环-3-基)二十四烷酸胺及其制备方法
CN115304569A (zh) * 2022-09-14 2022-11-08 浙江世佳科技股份有限公司 一种以4-甲基苯磺酸吡啶鎓为催化剂的端醇羟基保护方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3476656D1 (en) 1983-05-25 1989-03-16 Takeda Chemical Industries Ltd Derivatives of beta-amino-gamma-trimethylammonio-butyrate, their production and use
US4632925A (en) 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
ITRM20050090A1 (it) * 2005-03-02 2006-09-03 Sigma Tau Ind Farmaceutiche Riunite Spa Derivati dell'acido ammino-butanoico inibitore della cpt.
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
JP2009545549A (ja) * 2006-08-02 2009-12-24 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Ｃｐｔ阻害剤としての４−トリメチルアンモニウム−３−アミノブチレートおよび４−トリメチルフォスフォニウム−３−アミノブチレート誘導体
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
AU2009242240B2 (en) 2008-04-29 2011-09-22 F. Hoffmann-La Roche Ag 4-dimethylaminobutyric acid derivatives

Also Published As

Publication number Publication date
AR073842A1 (es) 2010-12-09
RU2474573C2 (ru) 2013-02-10
CL2009001006A1 (es) 2010-06-04
US20090270505A1 (en) 2009-10-29
JP5474047B2 (ja) 2014-04-16
EP2268606B1 (en) 2014-08-06
TW200946106A (en) 2009-11-16
KR20100127306A (ko) 2010-12-03
JP2011518205A (ja) 2011-06-23
PE20091735A1 (es) 2009-11-13
US20120289554A1 (en) 2012-11-15
EP2268606A1 (en) 2011-01-05
TWI369344B (en) 2012-08-01
CA2722087A1 (en) 2009-11-05
CN101952243B (zh) 2014-07-16
CN101952243A (zh) 2011-01-19
WO2009132978A1 (en) 2009-11-05
RU2010148532A (ru) 2012-06-10
AU2009242240B2 (en) 2011-09-22
ZA201005321B (en) 2011-04-28
CA2722087C (en) 2013-07-09
US8344027B2 (en) 2013-01-01
AU2009242240A1 (en) 2009-11-05
KR101225223B1 (ko) 2013-01-22
ES2507089T3 (es) 2014-10-14
BRPI0911159A2 (pt) 2015-10-06
IL206524A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
BR112014001801A2 (pt) indazóis
IN2012DN01233A (es)
BR112014015363A8 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
NZ608116A (en) Triazine-oxadiazoles
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
EA201270216A1 (ru) Фармацевтический состав
IN2012DN03182A (es)
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MX349373B (es) Nuevos derivados de pirazina.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2010008196A (es) Derivados de acido 4-dimetilaminobutirico.
UA109037C2 (uk) Триазолопіридини
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.

Legal Events

Date Code Title Description
FG Grant or registration